|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_ocn947118221 |
003 |
OCoLC |
005 |
20231120112104.0 |
006 |
m o d |
007 |
cr cnu|||unuuu |
008 |
160422t20162016ne ob 001 0 eng d |
040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d IDEBK
|d YDXCP
|d OCLCF
|d OPELS
|d EBLCP
|d OCLCQ
|d U3W
|d D6H
|d WYU
|d OCLCQ
|d LQU
|d S2H
|d OCLCO
|d OCLCQ
|
019 |
|
|
|a 950463432
|a 1151750397
|a 1152530885
|a 1153159226
|a 1153955611
|a 1154483639
|a 1155230141
|a 1162446422
|a 1163623794
|a 1164676314
|a 1175705546
|a 1182523060
|a 1183409415
|
020 |
|
|
|a 9780128035696
|q (electronic bk.)
|
020 |
|
|
|a 0128035692
|q (electronic bk.)
|
020 |
|
|
|z 9780128035313
|
035 |
|
|
|a (OCoLC)947118221
|z (OCoLC)950463432
|z (OCoLC)1151750397
|z (OCoLC)1152530885
|z (OCoLC)1153159226
|z (OCoLC)1153955611
|z (OCoLC)1154483639
|z (OCoLC)1155230141
|z (OCoLC)1162446422
|z (OCoLC)1163623794
|z (OCoLC)1164676314
|z (OCoLC)1175705546
|z (OCoLC)1182523060
|z (OCoLC)1183409415
|
050 |
|
4 |
|a RC647.C55
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
082 |
0 |
4 |
|a 616.1/57
|2 23
|
100 |
1 |
|
|a Nguyen, Andy,
|e author.
|
245 |
1 |
0 |
|a Management of hemostasis and coagulopathies for surgical and critically ill patients :
|b an evidence-based approach /
|c Andy Nguyen, Amitava Dasgupta, Amer Wahed.
|
264 |
|
1 |
|a Amsterdam, Netherlands :
|b Elsevier,
|c [2016]
|
264 |
|
4 |
|c �2016
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed April 28, 2016).
|
520 |
|
|
|a Management of Hemostasis and Coagulopathies for Surgical and Critically Ill Patients: An Evidence-Based Approach offers a concise guide to a sub-specialty of transfusion medicine from the clinical laboratory perspective. It focuses on the clinical tests that may be done during preoperative assessment, intraoperative, and postoperative assessment and management of surgical or critically ill patients. Management of hemostasis and coagulopathies is approached from an evidence-based perspective-the coagulation status of a patient according to the laboratory test results. Algorithms and decision-support software, designed by the authors, guide clinicians with an additional tool to base transfusion dosage on specific laboratory results, including the use of an artificial neural network for predicting more accurate blood use. Chapters reflect the experience of all three authors who have successfully applied the algorithm for better patient management as well as decreased wastage of expensive blood products, from both the clinical laboratory/pathology and clinical medicine perspective. This book will appeal to a broad section of clinical laboratory and medical practitioners from hematopathology, to internal medicine, surgery, and anesthesiology. For hematopathologists and pathologists who are involved in laboratory medicine and transfusion medicine, this book will help them understand the proper utilization of blood products and how to avoid unnecessary waste and costs for the hospital. For general surgery practitioners, this book will provide practical guidelines on how to use blood products rationally for best medical practice. Internists will also gain insight from this book, learning which patients are at higher risk of bleeding during surgery so that they can alert their clinical colleagues.
|
505 |
0 |
|
|a Front Cover; Management of Hemostasis and Coagulopathies for Surgical and Critically Ill Patients; Copyright Page; Contents; Preface; 1 Coagulation-Based Tests and Their Interpretation; 1.1 Introduction; 1.2 Complete Blood Count; 1.3 Tests for Platelet Function; 1.3.1 PFA-100; 1.3.2 VerifyNow; 1.3.3 Plateletworks; 1.3.4 Platelet Aggregation; 1.4 Prothrombin Time; 1.5 Partial Thromboplastin Time; 1.6 Thrombin Time; 1.7 Fibrinogen Level; 1.7.1 D-Dimer; 1.7.2 Antithrombin III Level; 1.7.3 Mixing Study; 1.8 Thromboelastography; 1.8.1 Platelet Mapping; 1.8.2 Anti-Xa Assay.
|
505 |
8 |
|
|a 1.8.3 Plasma-Diluted Thrombin Time1.9 Heparin-Induced Thrombocytopenia; 1.9.1 Bleeding Patient With Normal Coagulation Tests; 1.10 Conclusions; References; 2 Blood Bank Testing and Blood Products; 2.1 Introduction; 2.2 Blood Collection and Testings; 2.2.1 ABO/Rh(D) Typing; 2.2.2 Antibody Screen; 2.2.3 Antibody Identification by Extended (Panel) Testing; 2.2.4 Implications of the Presence of Antibodies; 2.2.5 Crossmatch; 2.3 Blood Components; 2.3.1 Whole Blood; 2.3.2 Packed Red Blood Cells; 2.3.3 Fresh Frozen Plasma; 2.3.4 Plasma Variants; 2.3.5 Platelets; 2.3.6 Cryoprecipitate.
|
505 |
8 |
|
|a 2.4 Release of Blood Products2.4.1 Autologous Blood; 2.4.2 Transfusion Reactions; 2.4.3 Transfusion-Related Acute Lung Injury; 2.4.4 Transfusion-Related Graft-Versus-Host Disease; 2.5 Transfusion Reaction Workup; 2.5.1 RhIg; 2.6 Conclusions; References; 3 Pharmacotherapy With Antiplatelet, Anticoagulant, and Their Reversing Agents; 3.1 Introduction; 3.2 Antiplatelet and Anticoagulant Agents: An Overview; 3.3 Reversing Agents: An Overview; 3.4 Aspirin; 3.4.1 Monitoring Aspirin Therapy; 3.5 Adenosine Diphosphate Receptor Blockers; 3.5.1 Ticlopidine and Clopidogrel; 3.5.2 Prasugrel.
|
505 |
8 |
|
|a 3.5.3 Ticagrelor3.5.4 Cangrelor; 3.5.4.1 Monitoring Therapy with ADP Receptor-Blocking Agents; 3.6 Glycoprotein IIB/IIIA Inhibitors; 3.7 Phosphodiesterase Inhibitors; 3.8 Thrombin Receptor Antagonist; 3.9 Warfarin; 3.9.1 Reversal of Warfarin Therapy; 3.10 Heparin and Low-Molecular-Weight Heparin; 3.10.1 Low-Molecular-Weight Heparin; 3.10.2 Reversible Agents for Heparin; 3.11 Direct Thrombin Inhibitors; 3.11.1 Parenterally Administered Direct Thrombin Inhibitors; 3.11.2 Orally Administered Direct Thrombin Inhibitors; 3.12 Factor XA Inhibitors; 3.13 Conclusions; References.
|
505 |
8 |
|
|a 4 Antiplatelets and Anticoagulants4.1 Introduction; 4.2 Monitoring and Reversal for Coumadin; 4.2.1 Reversal of Coumadin With Supratherapeutic INR; 4.3 Monitoring and Reversal for Unfractionated Heparin; 4.3.1 Reversal of UFH; 4.4 Monitoring and Reversal for Bivalirudin (Angiomax); 4.5 Monitoring and Reversal for Dabigatran; 4.6 Monitoring and Reversal for Rivaroxaban (Xarelto) and Apixaban; 4.7 Monitoring for Aspirin and P2Y12 Platelet Inhibitors; 4.8 Bridging Anticoagulants for Surgery; 4.9 Conclusions; References; 5 Preoperative Assessment of Patients; 5.1 Introduction; 5.2 History.
|
650 |
|
0 |
|a Blood coagulation disorders.
|
650 |
|
0 |
|a Hemostasis.
|
650 |
|
2 |
|a Blood Coagulation Disorders
|0 (DNLM)D001778
|
650 |
|
2 |
|a Hemostasis
|0 (DNLM)D006487
|
650 |
|
6 |
|a Sang
|x Troubles de la coagulation.
|0 (CaQQLa)201-0016719
|
650 |
|
6 |
|a H�emostase.
|0 (CaQQLa)201-0005501
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
650 |
|
7 |
|a Blood coagulation disorders.
|2 fast
|0 (OCoLC)fst00834698
|
650 |
|
7 |
|a Hemostasis.
|2 fast
|0 (OCoLC)fst00955125
|
700 |
1 |
|
|a Dasgupta, Amitava,
|d 1958-
|e author.
|
700 |
1 |
|
|a Wahed, Amer,
|e author.
|
776 |
0 |
8 |
|i Print version:
|a Nguyen, Andy D.
|t Management of Hemostasis and Coagulopathies for Surgical and Critically Ill Patients : An Evidence-Based Approach.
|d San Diego : Elsevier Science, �2016
|z 9780128035313
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128035313
|z Texto completo
|